XPAR
BOI
Market cap542mUSD
Jul 09, Last price
27.30EUR
1D
1.11%
1Q
1.49%
Jan 2017
-67.57%
Name
Boiron SA
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Boiron S.A., founded in Messimy, France, in 1932, is a pharmaceutical company dedicated to the production and global sale of homeopathic medicines. Its market presence spans France, the broader European continent, North America, and numerous international territories. The company's offerings range from non-proprietary and proprietary formulations to a variety of branded homeopathic treatments. Among its prominent branded homeopathic products are Oscillococcinum, targeting influenza symptoms like fever, chills, headaches, and body aches; Stodal and Stodaline, developed for cough relief; Arnigel, for the localized adjunctive treatment of benign trauma without open wounds; Camilia, designed to alleviate teething problems in babies; and Sédatif PC, prescribed for anxiety, emotional distress, and minor sleep disorders. Additional homeopathic solutions include Coryzalia, for cold symptoms and rhinitis; Homéoptic, to soothe eye discomfort and irritation in all age groups; and Homéovox, for vocal disturbances. Beyond its core homeopathic range, Boiron also provides a selection of other health and wellness products. These encompass dietary supplements; the Dermoplasmine series (stick, balm, and mousse) for addressing dry lips and skin; Mag' Nuit, a formulation to assist with falling asleep; Arnitrosium, for joint pain; Castor Equi Boiron ointment, for cracked skin treatment; and Storinyl, a syrup to manage colds. Furthermore, the company offers herbal medicines, such as Canephron, which promotes diuresis and improved urinary elimination, alongside moisturizing baby milk and medical devices, including a range of COVID-19 self-tests and rapid antigenic tests. Boiron's products reach consumers through a comprehensive distribution network comprising dedicated centers, pharmacies, pharmacy chains, wholesalers, grocery stores, drugstores, health food stores, and various online retail channels.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||